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Objective: This study investigates the relationship between the cost of coronary
artery bypass graft surgery and both hospital size and case volume.
Methods: Retrospective administrative and cost data were obtained for all 12,774
patients who underwent isolated coronary bypass surgery at 12 Massachusetts hos-
pitals during 1995 and 1996. Hospitals were stratified by number of operating beds
into 3 groups (group I, <250 beds; group II, 250-450 beds; group III, >450 beds).
Total (diagnosis-related groups 106 + 107) annual coronary bypass cases per hos-
pital varied from 271 to 913 (mean 532). Univariate and multivariable analyses
were used to study the relationship between the direct and total cost and a number
of patient (age, sex, acuity class, payer) and hospital (bed capacity, annual case vol-
ume per diagnosis-related group, cardiothoracic residency) predictor variables. For
each hospital, we also studied the relationship between changes in coronary bypass
case volume and the corresponding changes in average cost from 1995 to 1996.
Results: Scatterplots revealed a broad range of mean direct cost of coronary bypass
surgery among hospitals with comparable case volumes. When annual cases were
analyzed as continuous variables, there was no linear relationship of case volume
with direct or total cost of coronary bypass (r = –0.05 to +0.08) for any diagnosis-
related group or year. When hospital bed capacity and case volume were grouped
into strata and studied by analysis of variance, there was no evidence of an inverse
relationship between these variables and cost. In multivariable analysis, patient acu-
ity class and diagnosis-related group were the most important predictors of cost.
Beds and case volume met inclusion criteria for most models but added little to the
“explanation” of variability R2, often less than 1%. Finally, substantial interhospital
differences were noted in the magnitude and direction (direct vs inverse) of their
1995 to 1996 change in volume versus change in cost.
Conclusions: Within the range of hospital size and case volume represented in this
study, there is no evidence that either variable is related to the cost of performing
coronary bypass surgery. Massachusetts hospitals appear to function on different
segments of different average cost curves. It is not possible to predict the relative
cost of coronary bypass grafting at a given hospital based primarily on volume. 
Numerous factors have been postulated to influence the clinicaloutcome and cost of coronary artery bypass graft surgery(CABG). These include preoperative clinical status (age, sex,race, left ventricular dysfunction, reoperative or emergencysurgery, diabetes, renal failure, chronic obstructive pulmonarydisease), surgeon, postoperative morbidity and mortality, hospital
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case volume, geographic location, the presence of a resi-
dency teaching program, and payer.1-13 Institution or pro-
gram case volume (and often, by implication, hospital size)
is widely believed to be inversely related to both mortality
(“practice makes perfect”) and cost (“economies of scale”).
The link between hospital volume and clinical outcome
has been studied extensively11,14,15 since the pioneering
work of Luft, Bunker, and Enthoven15 more than two
decades ago. Because surgical procedures, especially
CABG, have well-defined morbidity and mortality end
points, they have been the major focus of such research. On
the basis of its presumed relationship to quality, volume has
been used as a criterion for referral and as a minimum licens-
ing threshold for hospitals and physicians.16 It has also been
used as a basis for preferential government and private con-
tracts. However, questions have recently emerged regarding
this putative relationship. Some have speculated that pro-
gram volume and quality may appear related not because
“practice makes perfect” but because of “selective referral”
to historically high quality hospitals,16 which tends to rein-
force and perpetuate their reputation. Recent reviews from
The Society of Thoracic Surgeons,17 the Veterans Affairs
hospital system,18 and an independent meta-analysis19 have
also demonstrated that higher mortality rates occur primari-
ly in very low volume programs (<100 cases per year). The
results of such studies are dependent on the degree to which
the data are adjusted for case-mix and time period,19 with
more recent data showing less significant relationship
between volume and mortality.19,20 The previously demon-
strated inverse relationship between individual surgeon vol-
ume and operative mortality in New York was no longer sta-
tistically significant in more recent reports.21 In a similar but
independent study of 97,137 CABGs performed in New York
between 1990 and 1995, there was also no observed volume-
mortality relationship.20 Hannan16 speculates that quality
initiatives may mitigate the effect of volume. Overall, there
appears to be a growing realization that volume criteria are
both crude and arbitrary, useful mainly as a first iteration
only if other data are unavailable.22 Objective measures of
actual surgeon performance and hospital process should be
used whenever possible.
The corollary relationship of cost to case volume, accept-
ed by many as proven fact, is based on even more problem-
atic and dated empiric studies. It is assumed by many insur-
ers, government officials, and health planners that larger
programs perform CABG procedures more cost effectively,
primarily because their fixed costs are distributed over more
patients. Interestingly, this “economies of scale” hypothesis
has not been tested in a multi-institutional study encom-
passing a broad range of program size and payers and using
modern data. A report by Cowper and associates1 using
1990 Medicare data identified hospital volume as a multi-
variable but not univariate cost predictor. However, only
Medicare patients were studied, the amount of cost variation
explained by volume is not specified, and the hospitals were
in diverse geographic regions. The revised 1996 American
College of Surgeons Guidelines for Standards in Cardiac
Surgery23 recommended 200 or more cases per program per
year for “efficient” functioning but provided no supporting
data. The American College of Cardiology/American Heart
Association guidelines for CABG4 cited the work of
McGregor and Pelletier,8 Showstack and associates,9 and
Finkler24 regarding the inverse relationship between out-
come (cost and length of stay) and volume, specifically the
decrease in cost that appears to occur above program vol-
umes of 1008 or 30024 cases per year. However, these stud-
ies are based on data from the 1970s and 1980s, and they do
not necessarily reflect current experience.
Finally, simplistic volume-cost hypotheses often fail to
acknowledge the potential interhospital variability of pro-
duction functions and average cost curves. It is impossible
to understand the economics of CABG within a given mar-
ket, including the relationship of volume to cost, without
considering such confounding factors.
The object of this study was to investigate the relationship
of hospital size and case volume to the cost of providing a
CABG procedure in Massachusetts during fiscal years 1995
and 1996. Although a small state, Massachusetts has a broad
range of hospital size, cardiac case volume, and academic
involvement, a well-defined market area, and regulatory
requirements that mandate the reporting of basic cost and
outcome data.
We attempt to answer some basic questions raised by the
“economies of scale” argument. Is “bigger” usually “better”
with regard to CABG cost efficiency? Should government
or private insurers who seek the lowest cost CABG provider
always look first to the largest program? From the relative
CABG volume at two hospitals, can one predict their rela-
tive costs? Will a hospital inevitably decrease its average
cost per procedure by increasing its volume?
Methods
Anonymous patient level data were available from HealthShare
Technology, Inc (Acton, Mass) for each of the 12,774 patients who
underwent isolated CABG (diagnosis-related group [DRG] 106-
107) at 12 Massachusetts institutions during fiscal years 1995 and
1996. One Veterans Affairs hospital was excluded.
Statistical analyses were performed with SAS Statistical
Software (release 6.1, SAS Institute, Inc, Cary, NC) and PASS
power analysis software (NCSS Statistical Software, Kaysville,
Utah). We performed one analysis of the entire group of 12,774
patients in which DRG and fiscal year were used as predictor vari-
ables. We also analyzed each DRG and fiscal year (FY) subgroup
(DRG 106–FY 95, DRG 106–FY 96, DRG 107–FY 95, DRG
107–FY 96) separately because of the substantial cost differences
between DRGs 106 and 107 for each year (P < .0001) and between
fiscal years 1995 and 1996 for each DRG (P < .0001).
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Six separate analyses were performed: (1) Scatterplots were ini-
tially used to explore the relationship between hospital case vol-
ume and direct cost. (2) The univariate relationship between cost
and multiple predictor variables was examined. Case volume was
analyzed as a continuous variable, with the use of individual
patient cost data and the case volume of the hospital at which that
patient had surgery. (3) Analysis of variance was used to study the
relationship between costs and strata of bed capacity and case vol-
ume. Both the overall P value and the Scheffé test for significant
pairwise comparisons were determined. (4) Multivariable analysis
was performed with log direct or total cost as the dependent vari-
ables. Direct cost represents the resource use directly attributable
to the CABG procedure. This is probably the most valid for com-
parative purposes, because methods of overhead allocation vary
among hospitals. Forward stepwise selection was used, with P
value < .15 necessary for inclusion in the model. A similar multi-
variable analysis was also performed using length of stay as an
alternative, process-related end point. (5) Cox proportional hazards
model was used, substituting direct cost for survival to eliminate
concern regarding the assumptions of traditional multiple regres-
sion models. Patients who died in the hospital were censored at
time of death because they would have continued to generate cost
had they survived.25,26 The proportional hazard assumption was
tested graphically with log-log curves for each significant variable.
(6) Finally, the percent change in DRG-specific case volume for
each hospital from 1995 to 1996 was determined and compared
with the corresponding changes in cost to see whether any consis-
tent relationship was present. A similar approach, using sequential
outcome data from individual hospitals as they increase or
decrease their volume, has been suggested as the most definitive
way to test the volume-quality relationship.16
For each patient, a number of predictor variables were available,
including those relating to the patient (clinical acuity class [refined
DRG27], age, sex), the hospital at which the operation was per-
formed (bed capacity, annual DRG-specific case volume, presence
of an approved cardiothoracic residency training program), and the
payer. Hospital bed capacity was based on the best available 1995
and 1996 data, and this information was used to group the hospi-
tals into 3 strata for analysis (group I, <250 beds, group II, 250-450
beds; and group III, >450 beds). Data from each distinct hospital
entity were analyzed separately although several institutions had
undergone corporate integration during the period of the study.
Outcome measures (eg, mortality and length of stay) were not
included as predictor variables. These are highly correlated with
cost and would have dramatically increased the R2 of the models,
but they would also have decreased our ability to determine the rel-
ative importance of other variables in which we were specifically
interested.
Charge data for each patient were obtained from the
Massachusetts Division of Health Care Finance and Policy. These
were converted to costs by means of the cost center–specific ratios
of costs to charges (RCC) derived from the Medicare Cost Report
(form 2552). This is a generally accepted and validated method
whose results are accurate to within 10%.28 The 1995 RCC was
used for both 1995 and 1996 data, because the 1996 RCC was
unavailable at the time of the analysis. Differences between RCCs
for successive years are generally small, and this is a close and
commonly used approximation (personal communication, Richard
Siegrist, Jr, president and chief executive officer, HealthShare
Technology, Inc, Acton, Mass).
Direct costs included both the fixed and variable components of
costs directly attributable to patient care. Total costs included direct
costs, hospital overhead allocation, and medical education costs.
Results
Of the 12 hospitals in the study, three were in bed group I in
both 1995 and 1996, and one hospital moved from group II
in 1995 to group I in 1996. Five hospitals were in group II
and three hospitals were in group III during both years.
Total (DRGs 106 + 107) annual CABG volume averaged
532 cases (range 271-913) during fiscal year 1995-1996.
Figure 1. Scatterplots of average direct cost versus case volume for each hospital by DRG and year.
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Figure 1 depicts scatterplots of hospital volume versus
average direct cost for each DRG and fiscal year. Hospitals
with similar case volume had widely disparate average
costs, and there was no linear relationship between costs
and volume. These observations support our belief that the
volume-cost relationship within the Massachusetts market
area cannot be described by a single average cost curve.
The remainder of the analyses were performed with disag-
gregate, patient-specific data. Univariate statistics for each
DRG and year are presented in Table 1. Medicare insurance,
female sex, and higher refined DRG class were associated
with higher direct and total costs. A cardiothoracic residency
program was associated with higher direct costs. Continuous
variables were analyzed by means of the Pearson correlation
coefficient. There was no linear relationship between case
volume and either direct or total cost (r = –0.05 to 0.08). Age
was similarly unrelated to cost (r = 0.13 to 0.15).
Table 2 presents an analysis of cost versus 3 strata of hos-
pital bed size using analysis of variance. A similar analysis
of cost versus strata of case volume is shown in Table 3.
There is no evidence of an inverse relationship between
costs and either hospital size or program volume.
Multivariable model results for the entire sample of
12,774 patients are presented in Tables 4 (direct cost) and 5
(total cost). Table 6 presents a similar analysis using length
of stay as an alternative end point. Other than DRG group,
acuity class was consistently the most important predictor in
all models. Case volume and hospital beds met entry crite-
ria for most of the models but added little, often a fraction
of 1%, to the “explanation” of cost variability R2. Subgroup
models for each DRG and year produced similar results, and
these are available on request from us. Power analysis was
performed for all multiple regression models. In all cases,
power exceeded 0.90 at α .05.
The proportional hazards assumption of the Cox model
was violated by the observed data, and consequently this
model was not used.
As depicted in Figure 2, A and B, there was no consistent
relationship between the percent change in case volume for
a given hospital during the fiscal years 1995 and 1996 and
its corresponding percent change in direct cost. The rela-
tionship between the changes in the two variables was direct
for some hospitals and inverse for others, and the magnitude
of change in cost for a given change in volume varied great-
ly. These findings suggest that hospitals are functioning on
different portions of their respective cost curves.
Discussion
The putative inverse relationship between CABG volume
and mortality (“practice makes perfect”) has been re-evalu-
ated in recent years and appears to be a valid concern only
for very low volume programs.17-21 Accumulated CABG
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TABLE 1. Univariate statistics
DRG 106–FY 95 DRG 106–FY 96
No. % Direct cost Total cost No. % Direct cost Total cost
All patients 3,018 100.0 15,021 29,288 3,347 100.0 13,949 27,303
Residency
No 1,291 42.8 14,700 29,744 1,391 41.6 13,145 26,958
Yes 1,727 57.2 15,260 28,947 1,956 58.4 14,521 27,549
P = .0444 .1502 .0001 .1903
Payer
Blue Cross 242 8.0 13,788 27,304 260 7.8 12,362 24,196
HMO 566 18.8 13,203 25,637 686 20.5 12,726 24,801
Medicare 1,787 59.2 15,916 30,991 1,889 56.4 14,632 28,650
Commercial 204 6.8 13,652 26,342 225 6.7 13,462 26,310
P = .0001 .0001 .0001 .0001
Sex
M 2,090 69.3 14,566 28,487 2,294 68.5 12,595 26,595
F 928 30.7 16,044 31,092 1,053 31.5 14,721 28,846
P = .0001 .0001 .0001 .0001
Refined DRG
Class 0 73 2.4 11,444 22,689 56 1.7 10,674 21,391
Class 1 560 18.6 11,224 22,338 684 20.4 10,840 21,548
Class 2 1,428 47.3 13,494 26,142 1,586 47.4 12,762 24,984
Class 3 957 31.7 19,794 38,553 1,021 30.5 18,056 35,087
P = .0001 .0001 .0001 .0001
DRG, Diagnosis-related group; FY, fiscal year; HMO, health maintenance organization.
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experience, better trained surgeons, improved medical stabi-
lization, standardized protocols, better myocardial protec-
tion and perfusion techniques, and other advancements have
permitted sicker patients to be operated on with significant-
ly improved clinical outcomes and cost efficiency.29-32
The relationship of CABG volume to cost is another firmly
entrenched yet unsubstantiated belief. Most CABG cost stud-
ies are single institutional and, with the exception of the work
of Denton, Luevanos, and Matloff,7 have focused primarily on
clinical predictors. They have demonstrated limited ability to
predict cost (R2 = 0.22-0.29),13,33,34 as did the only multi-insti-
tutional study by Cowper and associates1 (R2 = 0.25). The
relationship of cost, hospital size, and case volume has not
been analyzed in a modern, multi-institutional study encom-
passing both Medicare and non-Medicare patients.
To eliminate known geographic differences in cost, our
study focused on a single state with a substantial diversity of
programs. Massachusetts has a representative mix of hospi-
tals with regard to size, case volume, cardiothoracic resi-
dency programs, and payer distribution. Because of state-
mandated reporting, we were able to acquire basic clinical
and economic data for each patient and to test the signifi-
cance of multiple factors on cost.
Despite the use of multiple different statistical techniques
and both aggregate and disaggregate data, we were unable
to show any consistent relationship between cost and either
hospital beds or case volume. These results appear counter-
intuitive to the concept of “economies of scale” and conflict
with widely held beliefs. We believe our data suggest two
explanations. First, it is a fundamental misconception to
assume that the CABG production functions and average
cost curves of hospitals within a given market are homoge-
neous. Only in this situation would a single, simplistic vol-
ume-cost relationship be expected. It is essential to distin-
guish between (1) movement along a single hospital’s
average cost curve (Figure 3) as volume changes and (2) the
family of cost curves from different hospitals within a mar-
ket sector (Figure 4). The latter may vary in position, slope,
or shape, thus yielding different costs at any given volume
level. For a single hospital (see Figure 3), the average unit
cost typically decreases as volume increases because of the
distribution of fixed costs over a larger number of cases.35,36
At some point, a plateau is reached at which marginal cost
equals the average cost. For some hospitals, this plateau por-
tion is relatively broad,8,24,36 representing a range of excess
capacity over which volume has little impact on average
cost of a procedure (eg, in Figure 2, A and B, hospitals D, G,
and L had substantial 1995-1996 percent changes in volume
with little change in direct cost). Occasionally, rapid expan-
sion of CABG volume may exceed hospital resource capac-
ity, leading to “bottleneck” and opportunity costs. This may
result in an upturn in the average cost curve.
DRG 107–FY 95 DRG 107–FY 96
No. % Direct cost Total cost No. % Direct cost Total cost
3,049 100.0 10,516 20,230 3,360 100.0 10,206 19,676
1,100 36.1 10,056 19,886 1,146 34.1 9,752 19,554
1,949 63.9 10,776 20,424 2,214 65.9 10,441 19,740
.0038 .2497 .0002 .6031
258 8.5 10,399 20,399 269 8.0 9,496 18,417
620 20.3 9,326 17,638 803 23.9 9,442 17,961
1,705 55.9 11,204 21,603 1,750 52.1 10,872 21,032
249 8.2 9,235 17,702 232 6.9 9,480 18,416
.0001 .0001 .0001 .0001
2,290 75.1 10,371 19,893 2,536 75.5 10,039 19,417
759 24.9 10,954 21,247 824 24.5 10,721 20,476
.0350 .0091 .0008 .0070
242 7.9 8,285 16,028 191 5.7 8,434 16,136
778 25.5 8,579 16,733 914 27.2 8,423 16,333
1,411 46.3 9,971 19,092 1,565 46.6 9,778 18,834
618 20.3 15,073 28,874 690 20.5 14,028 26,996
.0001 .0001 .0001 .0001
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This volume-cost relationship applies to a single hospital.
It appears, however, that the cardiac programs in
Massachusetts have different “production functions” for the
CABG operation and thus different average cost curves. As
demonstrated in the hypothetical example in Figure 4, one
hospital (H2) may have a lower average cost curve than
another (H1). Its cost is less for any given level of volume,
and the volume required to achieve a given average cost per
procedure is lower. It is thus impossible to predict the com-
parative cost of CABG at two hospitals simply from their
respective volumes without knowing where this average
cost curve lies relative to that of their competitors.
Furthermore, data in Figure 2, A and B, suggest that hospi-
tals are functioning at different points on their respective
cost curves, and thus the impact of volume changes on each
hospital’s cost may differ greatly.
Like clinical outcome, CABG is a complex function of
many factors other than just volume, and these collective-
ly determine the position of a hospital’s average cost
curve. These factors include clinical case mix and acuity,
quality control (decreasing the high costs associated with
perioperative morbidity and mortality), standardized pro-
tocols, process efficiency, and practice patterns.37 They
may result in a favorable shift of a hospital’s average cost
Surgery for Acquired Cardiovascular Disease Shahian, Heatley, Westcott
TABLE 2. Hospital beds versus cost
Group Beds Patients Total cost SD P value Direct cost SD P value
DRG 106–FY 95
I <250 615 26,011 10,778 13,799 6,073
II 250-450 1,319 30,052 15,694 .0001* 15,607 7,576 .0001*
III >450 1,084 30,218 16,074 15,000 8,238
DRG 106–FY 96
I <250 1,033 25,604 10,463 13,124 5,655
II 250-450 1,032 28,420 15,870 .0001* 15,056 8,203 .0001†
III >450 1,282 27,773 11,769 13,724 6,309
DRG 107–FY 95
I <250 738 18,202 7,728 9,486 4,046
II 250-450 1,366 21,373 14,888 .0001* 11,363 8,098 .0001†
III >450 945 20,161 11,133 10,097 5,578
DRG 107–FY 96
I <250 1,018 19,382 8,990 9,850 4,707
II 250-450 1,193 19,373 11,378 .0487 10,477 5,636 .0143‡
III >450 1,149 20,253 8,622 10,240 4,706
SD, Standard deviation; DRG, diagnosis-related group; FY, fiscal year; P = Overall analysis of variance; significant Scheffé test comparisons: *I versus II
and III; †II versus I and III; ‡I versus II.
TABLE 3. Hospital cases versus cost
Group Cases Patients Total cost SD P value Direct cost SD P value
DRG 106–FY 95
I <200 683 29,753 16,562 14,558 6,948
II 200-350 1,251 28,229 13,106 .0041* 15,291 7,294 .1258
III >350 1,084 30,218 16,074 15,000 8,238
DRG 106–FY 96
I <200 335 31,716 16,589 15,201 6,744
II 200-350 1,372 25,740 12,874 .0001*† 13,973 7,382 .0009†
III >350 1,640 27,710 11,727 13,674 6,290
DRG 107–FY 95
I <200 577 22,061 13,375 10,516 5,830
II 200-350 2,043 19,924 12,773 .0002† 10,523 7,112 .9937
III >350 429 19,223 8,320 10,484 4,842
DRG 107–FY 96
I <200 576 20,817 13,642 9,768 5,803
II 200-350 1,459 18,957 8,590 .0002‡ 9,926 4,650 .0001*§
III >350 1,325 19,973 8,958 10,704 5,112
SD, Standard deviation; DRG, diagnosis-related group; FY, fiscal year; P = Overall analysis of variance; significant Scheffé test comparisons: *II versus III;
†I versus II and III; ‡II versus I and III; §I versus III.
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curve rather than simply relying on movement along that
curve. Interhospital differences in such factors affect rel-
ative cost at all levels of volume. Furthermore, the oppor-
tunity for excellence in these areas is not a function of
program size.
Caveats
Several potential concerns regarding our study must be
addressed. First, accurate cost data for CABG is notorious-
ly difficult to obtain, even at one’s own hospital. However,
the data used in our study were submitted to various state
Figure 2. A, The percent change in case volume for each hospital between fiscal years 1995 and 1996 (DRG 106) is
depicted in black bars along with the corresponding percent change in direct costs, depicted in gray hatched
bars. There is no linear correlation between the changes observed for the two variables across the spectrum of
12 hospitals (r = 0.005). Both the magnitude and the direction of the relationship varied. In some instances, both
variables increase; in others, both decrease. Only at 6 hospitals were the changes in the two variables inversely
related. B, Similar data are plotted for DRG 107. Again, there is no linear relationship (r = 0.267), and for only 5 hos-
pitals was the change in the two variables inversely related.
A
B
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and federal agencies by regulatory requirement, and they
should represent each hospital’s best estimate of its true
costs. There are probably no more accurate multi-institu-
tional cost data currently available.
The second caveat concerns our use of the refined DRG as
a clinical acuity index. The refined DRG27 is more common-
ly used as a generic, severity adjustment index for adminis-
trative data. Objections to the use of this method to compare
risk-adjusted mortality among hospitals have been discussed
extensively by Iezzoni,38 Hannan and colleagues,39 and Hartz
and Kuhn.40 Most important is the inability to distinguish
between comorbidities and complications. The refined DRG
performs relatively well predicting CABG mortality but does
so because it captures most important clinical events and
diagnoses, some of which are preterminal.41 This may permit
the risk-adjusted results of a hospital with high complication
rates to appear similar to those of another hospital treating
patients with higher preoperative acuity. Our study uses the
refined DRG as a measure of overall clinical acuity to assess
the relative importance of clinical versus nonclinical cost pre-
dictors. No assumptions are made as to whether the acuity
level resulted from preoperative comorbidities or postopera-
tive complications, only that the hospitalization entailed a
certain level of clinical complexity. Used in this context, we
believe the refined DRG is an appropriate tool.
Third, without a cardiac surgery–specific risk adjust-
ment algorithm in the Massachusetts administrative data-
base, we cannot exclude the possibility that some institu-
tions may have had higher costs because they attracted
more critically ill patients. Although risk-adjusted cost
data would clearly be preferable, such information is cur-
rently unavailable. In fact, we are unaware of any pub-
lished, multi-institutional cost studies that have used such
risk adjustment. Our Massachusetts data are comparable
with those used for most regional and national cost stud-
ies. Ideally, large risk-adjusted databases such as that
maintained by The Society of Thoracic Surgeons will
someday include cost data. Only then will it be possible to
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TABLE 4. Multivariable model for log direct cost
Variable Partial R 2 Model R 2 Parameter estimate P value
Refined DRG class 3 0.1802 0.1802 0.4364 .0001
DRG 107 0.1281 0.3084 –0.2854 .0001
Refined DRG class 2 0.0223 0.3306 0.1559 .0001
Age 0.0081 0.3387 0.0021 .0001
Bed group II 0.0070 0.3457 0.0739 .0001
Resident 0.0074 0.3531 0.0565 .0001
FY 96 0.0018 0.3549 –0.0392 .0001
Sex 0.0015 0.3564 –0.0328 .0001
Medicare 0.0013 0.3577 0.0332 .0001
Cases 0.0004 0.3581 0.0002 .0063
HMO 0.0002 0.3583 –0.0168 .0611
Bed group III 0.0002 0.3585 –0.0170 .0680
Refined DRG class 1 0.0001 0.3586 0.0229 .1251
DRG, Diagnosis-related group; FY, fiscal year; HMO, health maintenance organization.
TABLE 5. Multivariable model for log total cost
Variable Partial R 2 Model R 2 Parameter estimate P value
DRG 107 0.1795 0.1795 –0.2900 .0001
Refined DRG class 3 0.1377 0.3172 0.4268 .0001
Refined DRG class 2 0.0178 0.3350 0.1419 .0001
Age 0.0100 0.3450 0.0024 .0001
FY 96 0.0019 0.3469 –0.0261 .0001
Bed group III 0.0018 0.3487 0.0746 .0001
HMO 0.0014 0.3501 –0.0271 .0001
Bed group II 0.0013 0.3515 0.0360 .0001
Sex 0.0013 0.3527 –0.0323 .0001
Medicare 0.0005 0.3533 0.0292 .0010
Refined DRG class 1 0.0002 0.3534 0.0275 .0777
Resident 0.0001 0.3536 0.0244 .0903
Cases 0.0005 0.3541 –0.0002 .0018
DRG, Diagnosis-related group; FY, fiscal year; HMO, health maintenance organization.
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compare the true risk-adjusted cost of cardiac procedures
among programs.
As in most other studies of CABG costs, the ability of our
multivariable model to explain variability in cost (R2) was
limited.1,13,26,32-34 This suggests that other variables not in
the model influence cost or that the relationships are non-
linear.
Only two successive yearly data points were available on
each hospital’s average cost curve. This is arguably a limit-
ed number of observations on which to base any broad infer-
ences regarding the shape and location of these curves.
Finally, one should not extrapolate beyond the data set
used to develop a predictive model. The lack of association
of CABG cost with hospital size and case volume may not
necessarily be observed in areas with very small programs
or greater outcome variability. Our data do not answer the
question as to whether there is a lower limit or “threshold”
volume for a cost-efficient CABG program, because no
such programs were available for our study. An inverse rela-
tionship might be observed at the very lowest limits of pro-
gram size and conversely in those few very large programs
that may enjoy true “economies of scale.” However, our data
encompass a broad range of hospital size and program vol-
ume that probably includes a majority of cardiac surgery
units in the United States.
Our results are also most relevant to a procedure like tra-
ditional CABG that is “mature,” having evolved over sever-
al decades. These procedures are frequently performed, and
Figure 3. A typical average cost curve. Average cost falls as vol-
ume increases and as fixed costs are distributed over a larger
number of procedures. This reaches a plateau, which may encom-
pass a broad range of volume, over which average and marginal
costs are equal, and volume does not significantly affect average
cost. In the short term, significant volume expansion may exceed
hospital resource capacity, and the resulting opportunity or bot-
tleneck costs may increase average CABG cost.
Figure 4. The hypothetical average cost curves for two hospitals
(H1 and H2). Comparing two hospitals, the more efficient H2 will
achieve a given level of cost (C1) at a significantly lower volume
of cases (V1) than that required (V2) to achieve the same cost level
at hospital H1. Conversely, at the same level of volume (V2), hos-
pital H2 will have significantly lower costs (C2) than hospital H1
(C1).
TABLE 6. Multivariable model for length of stay
Variable Partial R 2 Model R 2 Parameter estimate P value
Refined DRG class 3 0.1425 0.1425 5.8165 .0001
DRG 107 0.0553 0.1978 –2.7885 .0001
Age 0.0165 0.2143 0.0473 .0001
Refined DRG class 2 0.0108 0.2250 1.5964 .0001
FY 96 0.0090 0.2340 –1.2031 .0001
Bed group III 0.0052 0.2392 1.0796 .0001
Sex 0.0020 0.2411 –0.6142 .0001
Medicare 0.0011 0.2423 0.3531 .0001
HMO 0.0003 0.2425 –0.4293 .0309
Commercial 0.0002 0.2427 –0.3872 .0714
Bed group II 0.0001 0.2429 0.1849 .1407
DRG, Diagnosis-related group; FY, fiscal year; HMO, health maintenance organization.
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there are standard techniques for surgery, perfusion, and
anesthesia. Our conclusions may not apply at an earlier
stage of a procedure’s evolution or to less frequently per-
formed or standardized procedures. Finally, they cannot
necessarily be extrapolated to other specialties.
Conclusion
Selection of a cardiac surgery provider should not be based
on the simplistic expectation of lower costs at large or high-
volume institutions. This is analogous to recent cautionary
findings regarding the volume-mortality relationship.17-21
Despite the appeal of describing complex phenomena with
simple models, such parsimony is rarely achievable. Like
clinical outcome, cost is determined by a complex mix of
factors. Cost reduction caused by movement along a hospi-
tal’s average cost curve may not be as significant as superi-
or process and quality control, which shift the entire curve
to a more favorable level.
All hospitals should constantly strive to improve the
process and quality of the CABG procedure. Health plan-
ners, insurers, corporations, and the government should
focus on observed clinical and financial outcomes rather
than on arbitrary volume standards. Small hospitals are fully
capable of being cost competitive, and larger programs
should not assume that volume alone will result in cost effi-
ciency.
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Discussion
Dr Timothy J. Gardner (Philadelphia, Pa). This report by Dr
Shahian and associates on the relationship between CABG case
volume and direct costs incurred was very well done and is quite
timely. At a recent meeting with the physician director of
Medicare’s Center for Health Plans and Providers, we were told
once again about the continued interest of the Health Care
Financing Administration (HCFA) in establishing “centers of
excellence” for, among other things, CABG. In HCFA’s original
proposal for such centers, the assumption was made that concen-
trating clinical volume for CABG and other high-volume proce-
dures at several rather than multiple sites will result in improved
quality outcomes and cost savings. This study is an important
demonstration that this assumption does not necessarily hold, at
least within a certain range.
I have a couple of observations for which I would appreciate Dr
Shahian’s responses. First, the smallest of these 12 hospitals in the
present report had 220 acute care beds, and the fewest number of
CABG cases done annually in any of the hospitals was 271.
Assuming that at least 15% to 30% more major cardiac cases were
done in each of these 12 hospitals, none represents a truly low vol-
ume center. At the time of the study, Massachusetts had and still
maintains, I believe, limited availability to cardiac surgery as a state
health policy, and the ratio of cardiac surgery units to population size
continues to be low in comparison with other regions in the country.
The same situation exists in New York State, where clinical outcomes
have been reported to have improved substantially during the past
decade, erasing the original discrepancy identified in quality out-
comes observed between high and low volume programs. There are,
however, a number of areas in the United States where CABG is
being done in much smaller hospitals and where the surgical numbers
are considerably below those seen in even the lowest volume
Massachusetts hospital. 
In the April 18 issue of Circulation, a study from Washington
University concluded that from 1984 to 1996, differences in angio-
plasty-related mortality between high and low volume hospitals
have narrowed significantly but have not been eliminated. Between
1993 and 1996, the mortality rate dropped from 2.5% to 1.7% in
low volume hospitals, that is, those performing fewer than 200
angioplasties a year, compared with a steady mortality rate of 1.3%
for higher volume institutions. I would ask Dr Shahian to comment
on whether he thinks there is a floor in CABG activity below
which quality and cost effectiveness may be threatened. 
Dr Shahian, you state in your paper that some small but high-
quality, well-organized cardiac surgical programs may function
with equal or greater efficiency than very large programs and that
the number of surgeons and other personnel is more manageable,
which may permit greater standardization of care. I think you have
thrown down the gauntlet to some of the larger programs. In addi-
tion, your data showed that programs in which residents are trained
are more costly. 
Do you think that the same well-functioning organization can
be achieved in programs of such small size that the surgeons
have to operate at two or more hospitals and where small cardiac
surgical groups are required to be responsive and available at
several sites simultaneously? I feel certain that there are some
logistic challenges that even the most skilled cardiac surgeons
cannot cope with adequately under these circumstances, and I
am sure there are some situations in which volume does affect
cost and quality. I would also comment that your cost analysis is
based on direct costs and not the associated indirect expenses
that are needed to maintain a cardiac surgery program in small
hospitals that have to expend quite a bit of money in starting up
these programs. 
Finally, you noted that Medicare patients, female patients, those
operated on in hospitals with residency programs, and those with
higher clinical acuity classes, as reflected by the refined DRG clas-
sification, had hospitalizations associated with higher direct costs.
On the other hand, among the continuous variables of age, size of
the hospitals, and clinical case volume, there was no relationship
with the direct costs. How is it that Medicare patients, most of
whom were 65 years or older, were noted to have greater associat-
ed direct costs while this relationship was not seen when the ages
of the patients were analyzed? 
Dr Shahian. You raise a very interesting point. In this paper we
did not address the lower limit or threshold level for cost-effective
functioning. I think it is a good statistical principle not to extrapo-
late the findings of a model beyond the range of the data set from
which the model was estimated. Thus, I would not want to say that
these findings could be extrapolated to a hospital doing 100 cases
a year, since no such programs were studied. I would not neces-
sarily even extrapolate these findings to other procedures in car-
diac surgery, and certainly not to other surgical specialties.
This study dealt with a mature procedure with which we all have
considerable experience. It may not be applicable to other less
mature and standardized procedures practiced by less experienced
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surgeons. Our result may not be applicable to other states having a
much greater variability in the size of the programs and the num-
ber of cases done. Such caveats notwithstanding, these observa-
tions were made within a state with a broad range of programs that
I suspect are representative of a large majority of the programs in
the country.
With respect to the issue of using direct versus total cost, we actu-
ally did the analysis for each and the results were comparable. The
reason we focused on direct costs is that the methods of determining
indirect costs vary tremendously between hospitals, and we thought
that direct costs were a better estimate of the true costs associated
with the procedure. 
Dr Gregory L. Kay (Los Angeles, Calif). I have a different per-
spective about volume. In California, we have 125 hospitals offer-
ing cardiac surgery services. Over 60% of these do fewer than 250
cardiac procedures, with more than 50% performing fewer than
200 cases a year. These are true “low volume” programs. Didn’t
you actually study what we would consider to be “medium vol-
ume” programs, which probably accounts for your results? 
Dr Shahian. I agree completely, and I state clearly in the paper that
there were no very low volume programs. I also believe that the case
volumes represented in this study reflect the experience in a vast major-
ity of the programs across the country, with the exception of states like
California, where deregulation has led to a proliferation of very low
volume programs.
Dr Francis Robicsek (Charlotte, NC). Just like this study, in our
study of several hospitals, we also found very poor correlation
between average cost and hospital size. We could really identify
only one statistically significant factor that influenced the cost, that
is, the rate of postoperative complications. It was evident that
while in the individual patient the chance of complications was
directly related to preoperative risk factors, in different programs
the rate of postoperative complications and costs varied widely
despite the fact that the preoperative patient clinical features of
their populations were comparable. 
In other words, while most if not all programs, regardless of their
size, may function with few complications and low costs in low-
risk patients, only programs with clinical excellence may do the
same in high-risk patients. To lower the costs, one may do one of
two things: either get rid of the poor-risk patient or get rid of the
bad surgeon. 
Dr Shahian. Thank you. I agree with your comments, but I
would emphasize that the surgeon with the lowest morbidity and
mortality may be at either a large or a small hospital.
Furthermore, other factors are critical in addition to the surgeon.
The process and flow of cardiac surgery in an institution, the
overall coordination of care, and the other members of the team
are equally important. I do not think that these factors are relat-
ed to hospital size. Every hospital, large and small, should strive
to improve the efficiency of operation.
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